Detalles de la búsqueda
1.
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data.
J Urol
; 205(2): 554-560, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33090917
2.
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
J Urol
; 203(4): 743-750, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31580749
3.
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Lancet Oncol
; 14(9): 893-900, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23871417
4.
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.
Anticancer Drugs
; 24(7): 743-53, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23652277
5.
Mechanism-Driven and Clinically Focused Development of Botanical Foods as Multitarget Anticancer Medicine: Collective Perspectives and Insights from Preclinical Studies, IND Applications and Early-Phase Clinical Trials.
Cancers (Basel)
; 15(3)2023 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36765659
6.
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
J Clin Oncol
; 40(28): 3301-3309, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35446628
7.
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
J Clin Oncol
; 39(12): 1371-1382, 2021 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33617303
8.
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium.
BJU Int
; 105(3): 317-21, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19888985
9.
Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.
Cancer Invest
; 26(1): 53-9, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18181046
10.
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
J Clin Oncol
; 36(10): 991-999, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29261439
11.
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107.
Kidney Cancer
; 1(2): 123-132, 2017 Nov 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30334014
12.
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.
Clin Genitourin Cancer
; 15(6): 635-641, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28579151
13.
Papillary renal cell carcinoma: current progress and future directions.
Clin Genitourin Cancer
; 12(2): 74-9, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24629521
14.
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.
J Natl Cancer Inst
; 106(4): dju013, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24565955
Resultados
1 -
14
de 14
1
Próxima >
>>